September 2007. Volume 3. Number 3

In young women without previous infection, quadrivalent vaccine against human papillomavirus, prevents high-grade cervical lesions associated with HPV-16 and HPV-18

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27
Reviewers: Orejón de Luna G1, Ochoa Sangrador C2.
1CS General Ricardos. Madrid. España.
2Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
Correspondence: Gloria Orejón de Luna. Email: gloriaglo04@gmail.com
Reception date: /08/2007
Acceptance date: 18/08/2007
Publication date: 01/09/2007

Abstract


How to cite this article

Orejón de Luna G, Ochoa Sangrador C. Una vacuna cuatrivalente contra el virus del papiloma humano, previene las lesiones cervicales de alto grado de malignidad asociadas a los serotipos 16 y 18, en mujeres jóvenes sin infección previa. Evid Pediatr. 2007;3:77.

AVC | Critically appraised articles

The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27
Reviewers: Orejón de Luna G1, Ochoa Sangrador C2.
1CS General Ricardos. Madrid. España.
2Servicio de Pediatría. Hospital Virgen de la Concha. Zamora. España.
Correspondence: Gloria Orejón de Luna. Email: gloriaglo04@gmail.com
Reception date: /08/2007
Acceptance date: 18/08/2007
Publication date: 01/09/2007

How to cite this article

Orejón de Luna G, Ochoa Sangrador C. Una vacuna cuatrivalente contra el virus del papiloma humano, previene las lesiones cervicales de alto grado de malignidad asociadas a los serotipos 16 y 18, en mujeres jóvenes sin infección previa. Evid Pediatr. 2007;3:77.

References

  1. Villa L, Costa R, Petta C, Andrade R, Ault K, Giuliano A, et al. Prophylactic quadrivalent human papillomavirus (Type 6,11,16 and 18) L1 virus-like particle vaccine en young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-8.
  2. Ruiz Contreras J. Las nuevas vacunas frente al papilomavirus humano en la prevención del cáncer de cérvix. Evid Pediatr. 2007;3:32.
  3. Koutsky LA, Ault K, Wheeler C, Brown D, Barr E, Alvarez F, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-51.
  4. Hampl M, Sayajuuri H, Wentzensen N, Bender H, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal and anal intraepitelial lesion and vulvar cancer. Obstet Gynecol. 2006;108:1361-8.
01/09/2007

Linked Comment